Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours.

ABSTRACT:

Objective

Somatostatin receptor analogues are well-established in the treatment of metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs), especially for symptom control in patients with the carcinoid syndrome, and to control tumour growth. However, they need to be discontinued before peptide receptor radionuclide therapy (PRRT) as they may saturate the somatostatin receptor 2 (SSTR2) and prevent binding of the radioactive ligand.

Design

We evaluated the effects of the novel somatostatin analogue paltusotine on ¹⁸F-SiTATE radioligand uptake and on GEP-NET cell viability in comparison to octreotide.

Methods

Paltusotine and octreotide were evaluated in varying concentrations in an ¹⁸F-SiTATE uptake assay using stable hSSTR2 over-expre

SUBMITTER: Wang K 

PROVIDER: S-EPMC12538274 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature